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Choriocarcinoma is a raremalignant tumor of the syncytiotrophoblast
and cytotrophoblast thatmay occur after any pregnancy. Approximately
one half of choriocarcinomas occur following a hydatidaform mole
and the remainder after other pregnancies, including normal ones
(Loukovaara et al., 2005). The incidence after a normal delivery is es-
timated to be 1 in 50,000 live births (Tidy et al., 1995). Although the
malignancy originates in the placenta, there is often widespread me-
tastasis, most often to the lungs, vagina, pelvis, brain, and liver
(Berkowitz and Goldstein, 1981).
While maternal choriocarcinoma is quite uncommon, simulta-
neous malignancy in both mother and infant occurs with far less fre-
quency. Infantile choriocarcinoma is thought to be of the same origins
as of maternal disease, and is prone to metastasis as well, usually to
the liver. Affected newborns often present with anemia, hepatomeg-
aly, and precocious puberty (van der Hoef et al., 2004).
Despite the aggressive nature of the tumor, it is extremely sensitive
to chemotherapeutic agents, making it a highly curablemalignancy. Be-
cause the syncytiotrophoblast and cytotrophoblast both secrete β-hCG,
plasma levels of the hormone are typically elevated with disease and
are used to follow, the response to treatment (Blohm et al., 2001).
The following details the presentation and management of a case
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A 33 year old gravida 1 para 0 pregnant woman had a relatively un-
complicated pregnancywith the exception of cramping at 12 weeks, he-
moptysis at 28 weeks, and rib pain at 36 weeks. Computed tomography
(CT) scan at 36 weeks showed bilateral numerous pulmonary nodules
measuring up to 3.5 cm as well as a 4×3 cm low attention lesion of
the left lobe of the liver and a small low attenuation lesion of the spleen;
however, this occurred at an outside institution andunfortunately, there
was no follow-up on these results. After spontaneous rupture of the
membranes she had an uncomplicated vaginal delivery at 37 weeks.
The newborn infant male was noted to have pallor; CBC demonstrated
a hematocrit of 21. The anemia was thought to be due to a fetomaternal
hemorrhage and he received a blood transfusion. His hemoglobin levels
returned to normal, and he and his mother were discharged home on
postpartum day 2.
The mother returned approximately one month later with debili-
tating shoulder pain, shortness of breath and abdominal distension.
She was immediately transferred via helicopter to our institution,
where she would be diagnosed and treated. CT scan revealed innu-
merable lesions in the lung, liver lesions now measuring 12.6 cm
and with evidence of subcapsular hematoma surrounding the left
lobe of the liver (Fig. 1), and the spleen containing a 5.4 cm enhancing
lesion as well. Hemoperitoneumwas noted. β-hCG level was obtained
and was found to be 4.9 million mIU/ml. A diagnosis of metastatic
choriocarcinoma was made based on the clinical presentation, CT
ﬁndings and elevated serum β-hCG.
Upon the diagnosis of the mother, the infant was brought back to
the hospital and was found to have a β-hCG level of 339,000 mIU/ml.
CT scan showed a 4.5×3.5 cm liver mass (Fig. 2), eight lung lesions
(the largest measuring 3 cm), as well as bilateral ocular lesions. Phys-
ical exam revealed his liver palpable 3 cm below the costal margin.
Based on these ﬁndings, the diagnosis in the mother and elevated
β-hCG levels, the diagnosis of disseminated infantile choriocarcinoma
was made. It was determined that the risks of tissue biopsy including
excessive bleeding outweighed the potential beneﬁts.
Treatment of choriocarcinoma in the mother
After diagnosis, the patient underwent an emergent selective he-
patic embolization and splenic artery embolization, as well as multi-
ple blood transfusions. A MRI of the brain was performed at that
time and was highly suspicious for brain metastasis. During her hos-
pital stay she was given a dose of Cisplatin and Etoposide (EP) on
Fig. 1. CT scan of the mother showing a 12.6 cm liver lesion and subcapsular hematoma
surrounding the left lobe of the liver.
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at that time was 15,000. The patient was started on Etoposide,
Dactinomycin and Methotrexate (EMA) and Cisplatin and Etoposide
(EP) chemotherapy regiment with EMA and EP alternated on a week-
ly basis for 6 weeks.
Approximately one year after delivery, the patient's β-hCG level
was b2 mIU/ml; she was feeling well, and had no signiﬁcant com-
plaints other than easy fatigability, paresthesias of her ﬁngers andFig. 2. CT scan of the baby showing a 4.5×3.5 cm liver mass.toes, and some hypoacusia, which seemed to be gradually improving.
Two years post-diagnosis, she still shows no evidence of disease, and
is currently on a birth control pill.
Treatment of choriocarcinoma in the infant
The patient began chemotherapy immediately after diagnosis.
The ﬁrst 5 cycles consisted of Bleomycin (.5 units/kg, 2 units, single
dose), Etoposide (3 mg/kg daily×5 days), and Cisplatin (.7 mg/kg
daily×5 days) based on the Children's Cancer Group (CCG) proto-
col 8891 for germ cell tumors (Rogers et al., 2004). Audiometry
tests after the ﬁfth cycle indicated high frequency hearing loss, so
HDMTX was given for the remaining 3 cycles as follows: Metho-
trexate (33 mg/kg, single dose) and Leucovorin (15 mg/m2). His
β-hCG levels were monitored throughout the treatment and de-
creased to normal (b2 mIU/ml) after 5 cycles. In total he received
8 cycles of chemotherapy on 21-day intervals.
He tolerated chemotherapy well with few complications. Following
theﬁrst cycle, therewas signiﬁcant bleeding into the livermass, causing
it to double in size. After the second cycle, he suffered severe adrenal in-
sufﬁciency due to high dose dexamethsone (used as an anti-emetic), ac-
companied by severe hypoglycemia (glucose 10 mg/dl) and a serum
cortisol level of 0. He received cortisol supplements for over two
months until his levels returned to normal.
His most recent MRI showed complete resolution of all lung me-
tastases and marked reduction in the size of the liver mass and eye le-
sions. Audiometry testing still showed high frequency hearing loss.
Two years later, he continues to show no evidence of disease with a
negative β-hCG.
Comment
Choriocarcinoma, amongst other forms of gestational trophoblas-
tic neoplasia (GTN), has been described at length inmedical literature.
Maternal choriocarcinoma is extremely rare, occurring in an estimat-
ed 1 in 50,000 live births (Tidy et al., 1995). Infantile choriocarcinoma
is even more rare; less than 30 cases have been described in the liter-
ature (van der Hoef et al., 2004). Newborn infants tend to presentwith
a characteristic clinical picture of anemia, hepatomegaly, and preco-
cious puberty (Blohm et al., 2001). Regardless of variation in clinical
presentation, β-hCG is raised in serum and/or urine due to the tro-
phoblastic origin of tumor cells (van der Hoef et al., 2004).
Here we report the successful treatment of choriocarcinoma in both
mother and infant. In both patients, diagnosis was made based on CT
scans, elevated serum β-hCG, and clinical ﬁndings. Approximately
one-quarter of infants with choriocarcinoma present with symptoms
at birth and diagnosis can be easily conﬁrmed with a serum β-hCG
(McNally et al., 2002). In our case, the diagnosis was easily reached
based on the clinical presentation of the mother. However, in the rare
instances when the mother has no GTN, infantile choriocarcinoma can
be easily misdiagnosed or missed. If an infant presents with anemia
and a liver mass, as did our patient, serum β-hCG levels are critical for
diagnosis because isolated elevation of β-hCG in the presence of liver
mass has been reported only in choriocarcinoma. β-hCG levels can be
followed throughout the treatment to assess the response to chemo-
therapy, and to detect recurrences in both mother and child. These tu-
mors are highly vascular and friable, so biopsy may be difﬁcult and
even dangerous (Yoon et al., 2007). As such, in the infant we describe,
treatment begun immediately without tumor biopsy.
Choriocarcinoma is a very aggressive malignancy and death may
result from delays in diagnosis. Therefore, early intervention –
which can be difﬁcult because of the rarity of the disease – is critical
for limiting the progression of disease. In infants, without appropri-
ate treatment, death usually occurs within 3 weeks of initial presen-
tation (Yoon et al., 2007). Fortunately, despite its aggressive nature,
this cancer responds very well to chemotherapeutic agents, even in
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survival, even in patients with cerebral metastases at presentation,
is approximately 80% (McNally et al., 2002). Both patients described
responded very well to chemotherapy, without signiﬁcant complica-
tions, and currently have shown no progression or recurrence of dis-
ease in the two years since diagnosis.
Patient neglect is never excusable, especially with the signs and
symptoms the mother presented with to her original physicians.
However, this instance does provide us with some education; the
fact that the tumor had progressed further and still resolved with
treatment speaks to this aggressive cancer's excellent response to
chemotherapy.
After completing her treatment, the mother was advised to begin
using birth control pills. Because a history of maternal choriocarcinoma
is associated with a risk of infantile choriocarcinoma in subsequent
pregnancies, current guidelines suggest thatwomenwith such a history
should be checked for β-hCG at 6 and 10 weeks following a subsequent
pregnancy, regardless of the outcome (Blohmet al., 2001;McNally et al.,
2002).Conﬂict of interest statement
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